Search research articles
Contact Us
Filters
Showing results (411-420 of 462) with videos related to
Page
of 47
Sort By:
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
October 12, 2010
Impact of thrombus aspiration on angiographic and clinical outcomes in patients with ST-elevation myocardial infarction
Jonathan Beaudoin, Jean-Pierre Dery, Philippe Lachance, et al.
The Canadian Journal of Cardiology
|
December 6, 2007
Outpatient percutaneous coronary intervention: Ready for prime time?
Olivier F Bertrand, Eric Larose, Robert De Larochellière, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
October 22, 2008
Impact of fractional flow reserve measurement on the clinical management of patients with coronary artery disease evaluated with noninvasive stress tests prior to cardiac catheterization
Philippe Lachance, Jean-Pierre Déry, Josep Rodés-Cabau, et al.
The Canadian Journal of Cardiology
|
September 12, 2009
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial
Olivier F Bertrand, Paul Poirier, Josep Rodés-Cabau, et al.
The American Journal of Cardiology
|
July 25, 2006
Usefulness of fractional flow reserve measurements to defer revascularization in patients with stable or unstable angina pectoris, non-ST-elevation and ST-elevation acute myocardial infarction, or atypical chest pain
Jean-Michel Potvin, Josep Rodés-Cabau, Olivier F Bertrand, et al.
The American Journal of Cardiology
|
August 19, 2007
Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting
Josep Rodés-Cabau, Alvaro Facta, Eric Larose, et al.
The Canadian Journal of Cardiology
|
December 6, 2007
Treatment delays in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction at the Quebec Heart and Lung Institute
Patrick Garceau, Jean-Pierre Déry, Philippe Lachance, et al.
The American Journal of Cardiology
|
September 18, 2012
Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention
Jimmy MacHaalany, Eltigani Abdelaal, Yoann Bataille, et al.
American Heart Journal
|
March 5, 2013
Successive transradial access for coronary procedures: experience of Quebec Heart-Lung Institute
Eltigani Abdelaal, Pierre Molin, Guillaume Plourde, et al.
Atherosclerosis
|
July 3, 2010
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
Olivier F Bertrand, Paul Poirier, Josep Rodés-Cabau, et al.
Page
of 47
Search research articles
Search
Showing results (411-420 of 462) with videos related to
Sort By:
Page
of 47
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
October 12, 2010
Impact of thrombus aspiration on angiographic and clinical outcomes in patients with ST-elevation myocardial infarction
Jonathan Beaudoin, Jean-Pierre Dery, Philippe Lachance, et al.
The Canadian Journal of Cardiology
|
December 6, 2007
Outpatient percutaneous coronary intervention: Ready for prime time?
Olivier F Bertrand, Eric Larose, Robert De Larochellière, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
October 22, 2008
Impact of fractional flow reserve measurement on the clinical management of patients with coronary artery disease evaluated with noninvasive stress tests prior to cardiac catheterization
Philippe Lachance, Jean-Pierre Déry, Josep Rodés-Cabau, et al.
The Canadian Journal of Cardiology
|
September 12, 2009
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial
Olivier F Bertrand, Paul Poirier, Josep Rodés-Cabau, et al.
The American Journal of Cardiology
|
July 25, 2006
Usefulness of fractional flow reserve measurements to defer revascularization in patients with stable or unstable angina pectoris, non-ST-elevation and ST-elevation acute myocardial infarction, or atypical chest pain
Jean-Michel Potvin, Josep Rodés-Cabau, Olivier F Bertrand, et al.
The American Journal of Cardiology
|
August 19, 2007
Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting
Josep Rodés-Cabau, Alvaro Facta, Eric Larose, et al.
The Canadian Journal of Cardiology
|
December 6, 2007
Treatment delays in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction at the Quebec Heart and Lung Institute
Patrick Garceau, Jean-Pierre Déry, Philippe Lachance, et al.
The American Journal of Cardiology
|
September 18, 2012
Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention
Jimmy MacHaalany, Eltigani Abdelaal, Yoann Bataille, et al.
American Heart Journal
|
March 5, 2013
Successive transradial access for coronary procedures: experience of Quebec Heart-Lung Institute
Eltigani Abdelaal, Pierre Molin, Guillaume Plourde, et al.
Atherosclerosis
|
July 3, 2010
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
Olivier F Bertrand, Paul Poirier, Josep Rodés-Cabau, et al.
Page
of 47